Consort Medical (LON:CSRT)‘s stock had its “buy” rating reaffirmed by investment analysts at Shore Capital in a note issued to investors on Thursday, ThisIsMoney.Co.Uk reports.
Separately, Numis Securities downgraded shares of Consort Medical to a “hold” rating in a research note on Thursday, June 6th.
Shares of CSRT stock opened at GBX 867.88 ($11.34) on Thursday. The company has a debt-to-equity ratio of 48.36, a quick ratio of 1.32 and a current ratio of 1.92. The stock has a market capitalization of $426.23 million and a price-to-earnings ratio of 25.45. Consort Medical has a one year low of GBX 700 ($9.15) and a one year high of GBX 1,294 ($16.91).
About Consort Medical
Consort Medical plc operates as a one-stop developer and manufacturer of drugs and premium drug delivery devices. It operates through two divisions, Bespak and Aesica. The company provides various life improving treatments to patients across worldwide through the design, development, and manufacture of medical devices for inhaled, injectable, nasal, and ocular drug delivery, as well as point of care diagnostics products.
See Also: Is it Safe to Invest in Commodities?
Receive News & Ratings for Consort Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Consort Medical and related companies with MarketBeat.com's FREE daily email newsletter.